Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 25

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 25
---
 on 1/27 Responses Immediately rejected by Deep Track Dynavax viewed as unconstructive because it insisted in greater representation and new conditions Immediately rejected by Deep Track and insisted on each of its prior terms Responded with proposal on 1/30 No response from Deep Track until its nomination notice on 2/18 We Worked Diligently and Sincerely to Negotiate a Peaceful Resolution…(1/2) Privileged and Confidential In 4 different settlement proposals over a 3 - month period we offered meaningful Board refreshment which would not compromise the Company’s long - term prospects Deep Track insisted it have direct Board representation now, and be unrestricted in its path to control the Board and/or continue to push for an outsized share repurchase

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track insisted it have direct Board representation now, and be unrestricted in its path to control the Board and/or continue to push for an outsized share repurchase Dynavax Proposal #4 (3/12) Deep Track Counter Proposal (3/20) Dynavax Response (3/20) Deep Track Response (3/22) Deep Track Counter Proposal (4/10) Dynavax Response (4/12) Deep Track Counter Proposal (4/17) Dynavax Response 4/25 New Directors Two Directors Santel (2025) Farrow or Mullette (2025) Three Directors Erkman (2025) 2 Other Deep Track Nominees (2025) Dynavax sent an email to Deep Track rejecting the 3/20 counter proposal but remains willing to engage with Deep Track in negotiating a constructive solution Deep Track sent an email to Dynavax that they were at an impasse and that Deep Track would be moving forward with a proxy contest Two Directors Santel (2027 / 2028) Erkman (2027 / 2028) Dynavax reiterated its prior 3/12 offer (i.e. Proposal #4) Two Directors Santel (2027) Erkman (2026) Dynavax reiterated its prior 3/12 offer (i.e. Proposal #4) Number of Incumbent Directors Stepping Down Two Directors Two incremental to two announced on 1/27 Three Directors Myers and two incremental to two